Get the Stockscreener App
1.54
0.00%
0.00
Pre-market:
1.55
0.01
+0.65%
Neuronetics Inc stock is traded at $1.54, with a volume of 1.60M.
It is up +0.00% in the last 24 hours and down -9.41% over the past month.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
See More
Previous Close:
$1.54
Open:
$1.55
24h Volume:
1.60M
Relative Volume:
0.71
Market Cap:
$107.17M
Revenue:
$151.64M
Net Income/Loss:
$-37.23M
P/E Ratio:
-3.9346
EPS:
-0.3914
Net Cash Flow:
$-21.18M
1W Performance:
+28.33%
1M Performance:
-9.41%
6M Performance:
+3.36%
1Y Performance:
-61.01%
1-Day Range:
$1.46
$1.59
1-Week Range:
$1.18
$1.59
52-Week Range:
$0.80
$4.8495
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
1.54 | 107.17M | 151.64M | -37.23M | -21.18M | -0.3914 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
Neuronetics, Inc. (STIM) Submits Form 8-K Reporting Shareholder Vote Results – Key Filing Details and Company Information - Minichart
What Does Jorey Chernett's Recent Buying Spree Signal for Neuronetics (STIM) - Kavout
Neuronetics (STIM) director Megan Rosengarten granted 30,000 RSUs, now holds 170,890 shares - Stock Titan
Director at Neuronetics (STIM) receives 30,000-share RSU grant - Stock Titan
Neuronetics (STIM) director awarded 30,000 RSUs vesting by 2027 - Stock Titan
Neuronetics (STIM) director Sheryl Conley awarded 30,000 RSUs in stock grant - Stock Titan
Neuronetics (STIM) director granted 36,250 RSUs, holdings rise to 625,017 shares - Stock Titan
Neuronetics (STIM) director Avinash Amin receives 30,000 RSU equity award - Stock Titan
Neuronetics (STIM) shareholders back directors, auditor and 2026 equity plan - Stock Titan
Neuronetics Inc stock (US63009R1005): Nasdaq shares steady as investors look beyond Q1 update - AD HOC NEWS
Neuronetics Inc stock (US63009R1005): shares little changed as investors weigh Q1 2026 update - AD HOC NEWS
PRISM MarketView Spotlights Seven Public Companies Advancing Mental Health Innovation During National Mental Health Awareness Month - StreetInsider
Large Neuronetics (STIM) holder discloses 15.17% stake and sole control - Stock Titan
STIMNeuronetics Inc Stock Price and Quote - Finviz
Neuronetics (STIM) Q1 2026 Earnings Transcript - AOL.com
Neuronetics Analyst Ratings and Price Targets | NASDAQ:STIM - Benzinga
Neuronetics Inc (STIM) Stock Price, Quote, News & History - Benzinga
Neuronetics, Inc. Signs $26,000/Month Consulting Agreement with Francis X. Brown III – 8-K Filing Details and Agreement Terms - Minichart
Neuronetics updates consulting agreement for interim financial officer By Investing.com - Investing.com South Africa
Neuronetics updates consulting agreement for interim financial officer - Investing.com
Neuronetics (NASDAQ: STIM) sets new monthly pay for interim finance chief - Stock Titan
Neuronetics, Inc. Appoints Francis X. Brown III as Accounting Officer, Effective as of May 5, 2026 - marketscreener.com
Neuronetics (STIM) ex-CFO corrects insider sale to 8,569 tax-withheld shares - Stock Titan
STIM PE Ratio & Valuation, Is STIM Overvalued - Intellectia AI
STIM SEC FilingsNeuronetics 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Buying: Jorey Chernett Acquires 100,000 Shares of Neuron - GuruFocus
Neuronetics 10% owner Chernett buys $117,000 in common stock By Investing.com - Investing.com South Africa
Neuronetics 10% owner Chernett buys $117,000 in common stock - Investing.com UK
Neuronetics (NASDAQ: STIM) large holder buys 100,000 shares - Stock Titan
Neuronetics(STIM) Stock Options Chain | Quotes & News - Moomoo
Neuronetics stock (US63009R1005): earnings move puts focus back on growth outlook - AD HOC NEWS
Neuronetics Revenue Rises as Clinic Business Expands - MyChesCo
Neuronetics partners with ANT Neuro on neuronavigation tech By Investing.com - Investing.com South Africa
Neuronetics and Ant Neuro announce strategic collaboration to integrate neuronavigation with Neurostar TMS treatment - marketscreener.com
Neuronetics partners with ANT Neuro on neuronavigation tech - Investing.com India
Neuronetics And Ant Neuro Announce Strategic Collaboration To Integrate Neuronavigation With Neurostar Tms Treatment - TradingView
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment - The Manila Times
Neuronetics (STIM) interim PAO reports 19,968 Common Stock shares - Stock Titan
Insider Buying: Jorey Chernett Acquires 475,000 Shares of Neuron - GuruFocus
Neuronetics: Jorey Chernett buys $636,500 in shares By Investing.com - Investing.com India
Neuronetics: Jorey Chernett buys $636,500 in shares - Investing.com UK
Neuronetics Insider Bought Shares Worth $636,500, According to a Recent SEC Filing - marketscreener.com
Neuronetics 10% Owner Purchased Shares Worth Over $636K - TradingView
Neuronetics | 4: Statement of changes in beneficial ownership of securities-10% Owner Chernett Jorey - Moomoo
Large Neuronetics (STIM) shareholder adds 475,000 shares in open-market buy - Stock Titan
Neuronetics stock (US63009R1005): Innovative Neurostimulation Leader - AD HOC NEWS
MSN Money - MSN
Neuronetics outlines $160M-$166M 2026 revenue outlook with focus on $2.5M-$3M annualized cost savings - MSN
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):